We show that ABCB1-overexpressing ovarian cancers are particularly sensitive to paclitaxel combined with lapatinib in the laboratory setting and that ABCB1 overexpression is common and predictive of paclitaxel sensitivity in patient-derived ovarian organoids. Here, ABCB1 is linked to ovarian cancer.